The therapeutic landscape of advanced HCC has changed significantly in recent years, with five tyrosine kinase inhibitors (TKIs) and an anti-vascular endothelial growth factor (VEGF) receptor 2 (VEGFR2) monoclonal antibody now approved across both the first- and second-line settings. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.